Mersana Therapeutics, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Mersana Therapeutics announces a definitive merger agreement with Day One Biopharmaceuticals, alongside continued operating losses and a strategic restructuring plan.
Mersana Therapeutics reported increased net losses and substantial doubt about its ability to continue as a going concern, despite positive early clinical data for its lead ADC candidate, Emi-Le.
Mersana Therapeutics announces Q1 2025 financial results and a strategic restructuring plan to extend cash runway into mid-2026.
Mersana Therapeutics' Q3 2024 report shows a significant decrease in net loss compared to the same period last year, driven by reduced operating expenses.
Mersana Therapeutics, a clinical-stage biopharmaceutical company, announced its second quarter 2024 financial results and updates on its antibody-drug conjugate (ADC) development programs.
Mersana Therapeutics reported a net loss of $19.3 million for the first quarter of 2024, while advancing its clinical programs for XMT-1660 and XMT-2056.